Alpine Immune Sciences, Inc.
ALPNDelisted May 20, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001626199
Alpine Immune Sciences, Inc. was delisted on May 20, 2024; its insiders filed their last Form 4 on May 20, 2024; 181 institutions reported holding it in 13F filings for Q1 2024, worth $2.56B in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:45 PM ET
Revenue flow, FY2023
Where the revenue went in FY2023, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2023: $32.2M (54.7% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 18, 2024 | Mar 23, 2023 | Mar 17, 2022 | Mar 18, 2021 | Mar 30, 2020 |
| Revenue | $58.9M | $30.1M | $23.4M | $9.34M | $1.74M |
| Operating expenses | $103.1M | $88.2M | $73.3M | $38.1M | $45.3M |
| Research and development | $80.9M | $70.2M | $58.7M | $27.2M | $35.8M |
| Selling, general and administrative | $22.2M | $18.0M | $14.6M | $10.9M | $9.47M |
| Operating income | -$44.3M | -$58.1M | -$49.9M | -$28.7M | -$43.6M |
| Interest expense | $98.0K | $476.0K | $816.0K | $775.0K | $338.0K |
| Income tax | $103.0K | $2.33M | -$87.0K | -$6.00K | $0 |
| Net income | -$32.2M | -$57.8M | -$50.3M | -$27.9M | -$41.9M |
| EPS, basic | $-0.64 | $-1.73 | $-1.98 | – | – |
| EPS, diluted | $-0.64 | $-1.73 | $-1.98 | – | – |
| Weighted shares, basic | 50.0M | 33.4M | 25.5M | – | – |
| Weighted shares, diluted | 50.0M | 33.4M | 25.5M | – | – |
| Margins and growth | |||||
| Operating margin | -75.2% | -193.4% | -212.7% | -308.0% | -2504.3% |
| Net margin | -54.7% | -192.1% | -214.7% | -299.3% | -2405.3% |
| Revenue growth, year over year | +95.8% | +28.2% | +151.1% | +436.5% | +146.8% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 18, 2024 | Mar 23, 2023 | Mar 17, 2022 | Mar 18, 2021 | Mar 30, 2020 |
| Cash and equivalents | $43.9M | $13.4M | $67.9M | $35.0M | $16.1M |
| Accounts receivable | $167.0K | $392.0K | $25.0M | – | – |
| Total current assets | $330.0M | $241.0M | $192.0M | $107.1M | $42.3M |
| Property, plant and equipment | $1.48M | $1.58M | $1.72M | $1.78M | $1.55M |
| Total assets | $379.9M | $286.7M | $255.9M | $144.1M | $54.1M |
| Accounts payable | $3.59M | $4.29M | $3.35M | $582.0K | $1.54M |
| Short-term debt | $0 | $3.38M | $4.62M | $2.53M | $418.0K |
| Total current liabilities | $42.0M | $58.0M | $69.8M | $41.2M | $8.68M |
| Long-term debt | – | $0 | $3.38M | $7.60M | $4.51M |
| Total liabilities | $51.9M | $107.3M | $135.0M | $81.9M | $24.6M |
| Shareholders' equity | $327.9M | $179.4M | $120.9M | $62.2M | $29.5M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 18, 2024 | Mar 23, 2023 | Mar 17, 2022 | Mar 18, 2021 | Mar 30, 2020 |
| Operating cash flow | -$79.0M | -$43.8M | -$15.2M | $30.1M | -$35.3M |
| Capital expenditures | $487.0K | $412.0K | $118.0K | $802.0K | $821.0K |
| Free cash flow | -$79.5M | -$44.2M | -$15.4M | $29.3M | -$36.2M |
| Stock-based compensation | $10.6M | $9.65M | $6.24M | $4.14M | $3.04M |
| Investing cash flow | -$55.6M | -$113.3M | -$52.5M | -$72.8M | $16.8M |
| Financing cash flow | $165.1M | $102.7M | $100.8M | $61.4M | $24.3M |
| Net change in cash | $30.6M | -$54.5M | $32.9M | $18.7M | $5.67M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 18.1% | 32.1% | 26.6% | 44.3% | 174.8% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| May 2, 2024 | 68.6M | +43.0% | SEC |
| Apr 9, 2024 | 65.6M | +36.7% | SEC |
| Mar 7, 2024 | 65.5M | +37.2% | SEC |
| Nov 9, 2023 | 58.1M | +26.5% | SEC |
| Aug 4, 2023 | 49.2M | +61.8% | SEC |
| May 5, 2023 | 48.0M | +58.2% | SEC |
| Mar 14, 2023 | 47.8M | +57.6% | SEC |
| Nov 8, 2022 | 45.9M | +57.1% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.